On Tuesday, Bristol and Merck said the U.S. Food and Drug Administration sent them a letter saying that Pargluva was approvable, but that more cardiovascular data would be needed if the drug were to be approved.

FORBES: Bristol, Merck Drug May Double Heart Risk

Bristol expects to file three new drug applications with the Food and Drug Administration within a year.

FORBES: Bristol-Myers Zeros In On Drugs

Bristol-Myers Squibb and AstraZeneca announced today that the Food and Drug Administration has approved their diabetes pill Kombiglyze, which combines the diabetes drug Onglyza with metformin, a generic drug.

FORBES: Good News For Bristol and Astra -- Maybe

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics license application (BLA) for ipilimumab in pre-treated advanced melanoma, and has moved its decision date from December 25, 2010 to March 26, 2011.

FORBES: Immune-Boosting Cancer Drug Hits FDA Delay

And Bristol has had a great record getting new drugs past the U.S. Food and Drug Administration, with six new medicines approved since 2000.

FORBES: Why Bristol And Sanofi Shouldn't Merge

Given the usual industry attrition rates, Evans says, Bristol's current pipeline could eventually deliver two potential blockbusters to the U.S. Food and Drug Administration's doorstep.

FORBES: The 'Buy' Case For Bristol-Myers

Bristol-Myers Squibb ( BMY - news - people ) learned that the Food and Drug Administration is extending until July 30 (from April 30) the time it is taking to review their application for the Type 2 diabetes treatment, saxagliptin, also known by its commercial name, Onglyza.

FORBES: Stock Of The Week